Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-24

Study Completion Date

2025-09-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In stage 3 NSCLC, treatment and follow-up are generally performed in a 'one-size-fits-all' manner. In the setting of metastatic lung cancer there has been considerable success identifying biomarkers, which allow treatments to be tailored and lead to more personalised medicine. In patients with stage 3 disease there exists a significant unmet clinical need for equivalent biomarkers to guide treatment decisions such as to identify poor responders, predict benefit from treatment and diagnose relapse before standard of care imaging. Recent advances have made it possible to detect and quantify circulating-tumour DNA in peripheral blood of patients with stage 3 NSCLC, a promising prognostic biomarker and a measure of minimal residual disease. In addition, the information contained in routine medical images and electronic patient reported outcome measure (ePROM) questionnaires can add further predictive power to circulating tumour DNA and other clinical factors to determine patient's outcome. There is scope to integrate biomarkers in treatment decision algorithms aiming to make personalised treatment modifications (e.g. decision to treat with immunotherapy or not). VIGILANCE is a highly exploratory observational study to understand how these biomarkers might inform a future hypothesis driven interventional study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer

NCT03258788

Non-Small Cell Lung Cancer

COMPLETED

Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer

NCT04749407

Non-small Cell Lung Cancer Stage III

UNKNOWN

Optimising Cancer Therapy And Identifying Causes of Pneumonitis USing Artificial Intelligence (COVID-19)

NCT04721444

Lung Cancer Covid19 Pneumonitis

COMPLETED

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

NCT06410300

Lung Cancer

RECRUITING

Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC

NCT05641870

Lung Cancer Stage III Lung Cancer Unresectable Lung Carcinoma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Stage III

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients diagnosed with stage 3 NSCLC

Patients will receive standard of care curative-intent radiotherapy treatment as decided by their primary oncologist. This includes radical radiotherapy, sequential chemoradiotherapy and concurrent chemoradiotherapy +/- consolidation immunotherapy.

No changes in treatment. Patients will have data collected at baseline, during radiotherapy and for one year following radiotherapy. This longitudinal collection will include blood for circulating-tumour DNA analysis, electronic PROMS and radiomic analysis of standard of care imaging.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histological or cytologically confirmed NSCLC.
* Unsuitable for surgery due to tumour or patient factors.
* Stage 3 A, B or C (TNM version 8).
* Planned to receive radical radiotherapy OR sequential chemoradiotherapy OR concurrent chemoradiotherapy +/- consolidation immunotherapy.
* Predicted life expectancy \>12 weeks.
* Ability to provide written informed consent.
* Willingness to comply with study procedures.

Exclusion Criteria

* Mixed non-small cell and small cell tumours.
* Adjuvant radiotherapy post-surgery.
* Participation in a study of an interventional study as part of lung cancer treatment.
* Recent/active malignant disease which might impact study results.
* Psychotic disorders/cognitive impairment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No